Acurx Pharmaceuticals, Inc. (ACXP)
1.43
+0.01
(+0.70%)
USD |
NASDAQ |
Sep 08, 16:00
1.435
0.00 (0.00%)
Pre-Market: 20:00
Acurx Pharmaceuticals Shareholders Equity (Quarterly) : 8.152M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.152M |
| March 31, 2026 | 7.013M |
| December 31, 2025 | 5.269M |
| September 30, 2025 | 3.637M |
| June 30, 2025 | 3.566M |
| March 31, 2025 | 2.311M |
| December 31, 2024 | 0.6151M |
| September 30, 2024 | 2.664M |
| June 30, 2024 | 3.428M |
| March 31, 2024 | 5.999M |
| December 31, 2023 | 4.667M |
| Date | Value |
|---|---|
| September 30, 2023 | 3.935M |
| June 30, 2023 | 6.216M |
| March 31, 2023 | 5.311M |
| December 31, 2022 | 7.315M |
| September 30, 2022 | 9.763M |
| June 30, 2022 | 8.785M |
| March 31, 2022 | 10.69M |
| December 31, 2021 | 12.41M |
| September 30, 2021 | 14.28M |
| June 30, 2021 | 15.52M |
| March 31, 2021 | 2.471M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 10.98M |
| Total Liabilities (Quarterly) | 2.833M |
| Current Ratio | 3.878 |